JNJ vs MELI: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and MercadoLibre, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
Johnson & Johnson · Healthcare
$270.68
+5.7% upside to fair value
Med Conviction
Grade C
High Quality
VS
MercadoLibre, Inc. · Consumer Cyclical
$1,828.94
+25.8% upside to fair value
Med Conviction
Grade B+
High Quality
QuantHub Verdict
MELI has more upside to fair value
(+25.8%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
MELI |
| Current Price |
$270.68 |
$1,828.94 |
| Fair Value Estimate |
$286.05 |
$2,300.00 |
| Upside to Fair Value |
+5.7%
|
+25.8%
|
| Market Cap |
$652.3B |
$92.7B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
20.2x
|
33.0x
|
| Price / Sales |
6.7x
|
2.6x
|
| Price / FCF |
35.3x
|
7.4x
|
| Revenue Growth YoY |
+6.6%
|
+49.8%
|
| Gross Margin |
67.9%
|
42.7%
|
| Operating Margin |
26.8%
|
8.3%
|
| Return on Equity |
25.7%
|
26.5%
|
| Dividend Yield |
1.95% |
0% |
| FCF Yield |
2.83%
|
13.44%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Johnson & Johnson is a 141,700-employee healthcare holding company operating two segments, Innovative Medicine (immunology, oncology, neuroscience, infectious disease, cardiovascular and metabolism, pulmonary hypertension) and MedTech (interventional solutions, orthopaedics, surgery, vision), founded in 1887 and headquartered in New Brunswick, New Jersey. Business quality is high on fundamentals:…
MercadoLibre operates Latin America's leading ecommerce marketplace alongside Mercado Pago payments, credit, logistics, advertising and loyalty products, creating a broad ecosystem with meaningful network effects and cross-sell. Business momentum remains strong: revenue and financial income grew 49.8% year over year in the most recent quarter to $10.169 billion, GMV increased 44%, TPV rose 56%, a…
Accumulation Zones
| Metric |
JNJ |
MELI |
| Zone Low |
$214.54 |
$1,725.00 |
| Zone High |
$243.14 |
$1,955.00 |
| In Buy Zone? |
No
|
Yes
|